ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/endometrial/metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological / Endometrial - Metastatic
28
trial(s) found.
NCT07623369
Advanced
Phase 1
Recruiting
An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors (
HH160-101
)
trispecific PD-1/VEGFA/CTLA4 antibody
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4215 - Southport - Tasman Oncology
NCT07341737
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours (
SL-28-FIH
)
allogeneic cell therapy,unspecified mechanism
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Hepatocellular carcinoma
Kidney cancer
Lung adenocarcinoma
Lung cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07286331
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy
anti-B7H4 antibody-drug conjugate
Endometrial carcinoma
NSW
2830 - Dubbo - Dubbo Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07262619
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Na\xEFve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors (
EIK1005-002
)
WRN inhibitor
anti-PD-1 monoclonal antibody
Cancer
Endometrial cancer
Gastric cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Solid tumour
dMMR solid cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - PASO Medical
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT07166094
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy (
RAINFOL-03
)
anti-FR-alpha antibody-drug conjugate
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT07044336
Advanced
Phase 3
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) (
D6900C00003
)
anti-B7H4 antibody-drug conjugate
Endometrial cancer
NOT Neuroendocrine carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06989112
Advanced
Phase 3
Recruiting
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer (
DE-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06952504
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (
TroFuse-033
/GOG-3119/ENGOT-en29)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06760819
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (
panSOHO
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
NOT Biliary tract cancer
NOT Colorectal cancer
NOT Non-small cell lung cancer
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - ICON Cancer Care
NCT06738966
Advanced
Phase 1
Recruiting
An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer (
BL0175-102
)
unknown drug class
Breast cancer
Endometrial cancer
Ovarian cancer
NCT06736704
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors (
SNV4818-101
)
PI3K alpha inhibitor,allosteric,mutant-selective
Breast cancer
Endometrial cancer
HPV-related cancer
Ovarian cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Cancer Research SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT06340568
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (
Fern-EC-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Endometrial cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06330064
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (
DS7300-203
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Cutaneous melanoma
Endometrial cancer
Gastrooesophageal adenicarcoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
NOT Sarcoma
Ovarian cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06253130
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors (
EIK1003-001
)
PARP1-selective inhibitor
Breast cancer
Endometrial cancer
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast Private Hospital
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06023862
Advanced
Phase 2
Recruiting
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma:
DOVE
(APGOT-OV07/ ENGOT-ov80 Study)
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Cervical clear cell carcinoma
Endometrial clear cell carcinoma
Ovarian clear cell carcinoma
Vulval clear cell adenocarcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05919264
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors (
FOG-001-101
)
CTNNB1/TCF4 inhibitor
Adamantinomatous craniopharyngioma
Aggressive fibromatosis
Cancer
Castrate-resistant prostate cancer
Colorectal cancer
Endometrial carcinoma
Hepatocellular carcinoma
Microsatellite instability-high colorectal cancer
Microsatellite stable colorectal cancer
Prostate cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
Endometrial cancer
Lung adenocarcinoma
Ovarian cancer
Squamous non-small-cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
NOT Breast cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT03564340
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16\xD7CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers (
R4018-ONC-1721
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,MUC16-targeting
Endometrial cancer
Fallopian tube cancer
Low-grade serous ovarian cancer
Ovarian cancer
Primary peritoneal serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12626000937314
Advanced
Phase 2
Not yet recruiting
IMPACT
- A phase 2 study of IMmunotherapy with Pembrolizumab and sACituzumab Tirumotecan in pMMR recurrent or advanced endometrial cancer
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Endometrial cancer
ACTRN12624001120561
Advanced
Not Applicable
Not yet recruiting
Patient Initiated Follow Up (PIFU) in Endometrial Cancer (
PECAN
) – a Randomised Pilot Feasibility Study
Endometrial cancer
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05642949
Advanced
Phase 1 / Phase 2
Unknown
Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors (
MHB036C-CP001EN
)
anti-Trop2 antibody-drug conjugate
Breast cancer
Endometrial cancer
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal squamous cell carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Prostate cancer
Small-cell lung cancer
Solid tumour
Sweat gland carcinoma
Urothelial carcinoma
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (25)
Not yet recruiting (2)
Unknown (1)
Recruitment Country and State
NSW (20)
VIC (17)
QLD (16)
SA (8)
WA (8)
NZ (1)
TAS (1)
Phase
Phase 1 (6)
Phase 1 / Phase 2 (11)
Phase 2 (4)
Phase 3 (6)
Trial Type
Advanced (28)
Cancer Therapy Class
PD-1
43%
PD-1/PD-L1
43%
VEGF
14%
FR-alpha
11%
ERBB2
11%
Trop2
11%
B7H4
7%
WRN
7%
oestrogen axis
7%
B7H3
7%
PARP
7%
PARP1-selective
7%
CTLA4
4%
VEGFA
4%
TIGIT
4%
EGFR
4%
CDK4
4%
CDK6
4%
ER
4%
PI3Kalpha
4%
ER alpha
4%
SMO
4%
ERBB3
4%
CTNNB1
4%
IL-2
4%
TP53
4%
TP53 Y220C
4%
IL-6
4%
MUC16
4%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (6)
3168 - Clayton - Monash Medical Centre (6)
2050 - Camperdown - Chris O'Brien Lifehouse (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (4)
2031 - Randwick - Scientia Clinical Research Ltd (4)
2109 - North Ryde - Macquarie University Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
5000 - Adelaide - Cancer Research SA (3)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6009 - Nedlands - Linear Clinical Research (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4215 - Southport - Tasman Oncology (1)
2830 - Dubbo - Dubbo Base Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3199 - Frankston - PASO Medical (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4215 - Southport - ICON Cancer Care (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
4215 - Southport - Gold Coast Private Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
2170 - Liverpool - Liverpool Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - One Clinical Research (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Endometrial cancer
Gynaecological cancer
Solid tumour
Ovarian cancer
Gastrointestinal cancer
Breast cancer
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
HPV-related cancer
Thoracic cancer
Viral-related cancer
Cervical cancer
Gastric cancer
Gastroesophageal cancer
HPV16-positive cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Pancreatic cancer
Pancreatobiliary cancer
Head and neck cancer
Male genital cancers
Prostate cancer
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Oesophageal cancer
Bladder cancer
Melanoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Epithelial Ovarian Cancer
Breast adenocarcinoma
Carcinoma
Kidney cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Triple-negative breast cancer
Urothelial carcinoma
Skin cancer
Endometrial carcinoma
Colorectal adenocarcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian adenocarcinoma
Clear cell renal cell carcinoma
Non-squamous non-small-cell lung cancer
Ovarian serous carcinoma
Prostate adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Lung adenocarcinoma
Biomarker-defined solid tumour
MSI-H/dMMR solid tumour
dMMR solid cancer
Cutaneous melanoma
Castrate-resistant prostate cancer
High-grade serous ovarian cancer
Sarcoma
Squamous non-small-cell lung cancer
Fallopian tube cancer
Non-melanoma skin cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Gastrooesophageal adenicarcoma
Platinum resistant ovarian cancer
Cervical clear cell carcinoma
Endometrial clear cell carcinoma
Ovarian clear cell carcinoma
Vaginal and vulvar cancer
Vulval cancer
Vulval clear cell adenocarcinoma
Adamantinomatous craniopharyngioma
Aggressive fibromatosis
Endocrine gland cancer
Microsatellite instability-high colorectal cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Pituitary gland cancer
Acral lentiginous melanoma
Cutaneous basal cell carcinoma
Cutaneous squamous cell carcinoma
Merkel cell carcinoma
Mesothelioma
Mucosal melanoma
Pleural mesothelioma
HER2-negative breast cancer
HER2-positive breast cancer
Low-grade serous ovarian cancer
Oesophageal squamous cell carcinoma
Sweat gland carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy